| HN-6.(-5662 12・22

WYELIT

002 Code 15 A 5. 2 / VEB(4) #1 File September 24, 2002

Ms. Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy
United States Patent and Trademark Office
Washington, D.C. 20231

Patent #22

Dear Ms. Ferriter:

This is in regard to the application for patent term extension of U.S. Patent No. 5,275,813 filed by the Regents of the University of California under 35 U.S.C. § 156. The veterinary biologic product claimed by the patent is Fel-O-Vax® FIV vaccine (Feline Immunodeficiency Virus Vaccine, Killed Virus), which was assigned VS Code No. 15A5.21.

A review of the Center for Veterinary Biologics official records indicates that this product was subject to a regulatory period before its commercial marketing, or use, as required under 35 U.S.C. § 156(a)(4). The applicable regulatory prelicense review under the Virus-Serum-Toxin-Act commenced with the submission of an Application for United States Veterinary Biological Product License dated May 4, 1998, and was completed with the issuance of the United States Veterinary Biological Product License dated March 14, 2002, a period of 1,390 days.

As required by 35 U.S.C. § 156(d)(2)(A), we will publish our determination of the applicable regulatory review period in the Federal Register and notify you of our determination.

Sincerely,

/s/ Richard E. Hill

Richard E. Hill, Jr., D.V.M. Director Center for Veterinary Biologics

cc: CVB-IC CVB-L

APHIS:VS:CVB-LPD:LRLudemann:ah:232-5785:9-24-02
G:\Prog\cvb-lpd\data\112\Correspondence\112_15A521_020924_patent2.doc

RTS 9-24-02 FPD 9-30-02 325-92 757